CO6311006A2 - Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas - Google Patents
Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altasInfo
- Publication number
- CO6311006A2 CO6311006A2 CO10127112A CO10127112A CO6311006A2 CO 6311006 A2 CO6311006 A2 CO 6311006A2 CO 10127112 A CO10127112 A CO 10127112A CO 10127112 A CO10127112 A CO 10127112A CO 6311006 A2 CO6311006 A2 CO 6311006A2
- Authority
- CO
- Colombia
- Prior art keywords
- agent
- regulatory
- cells
- pharmaceutical composition
- activates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención proporciona una composición farmacéutica para tratar una enfermedad autoimmune, que comprende un portador farmacéutico aceptable y un agente capaz de activar células T regulatorias CD4+CD25+, en donde la composición se va a administrar a un sujeto en una dosis del agente de 10 mg a 200 mg.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0804684A GB0804684D0 (en) | 2008-03-13 | 2008-03-13 | Humanized antibody |
GB0817810A GB0817810D0 (en) | 2008-09-29 | 2008-09-29 | Agent for treating disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6311006A2 true CO6311006A2 (es) | 2011-08-22 |
Family
ID=40677801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO10127112A CO6311006A2 (es) | 2008-03-13 | 2010-10-13 | Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas |
Country Status (19)
Country | Link |
---|---|
US (1) | US9512226B2 (es) |
EP (1) | EP2262838B1 (es) |
JP (2) | JP5795167B2 (es) |
KR (1) | KR20100135807A (es) |
CN (1) | CN102027016A (es) |
AU (1) | AU2009235622C9 (es) |
BR (1) | BRPI0909180A2 (es) |
CA (1) | CA2718191C (es) |
CO (1) | CO6311006A2 (es) |
ES (1) | ES2569217T3 (es) |
HK (1) | HK1151533A1 (es) |
HU (1) | HUE028962T2 (es) |
IL (1) | IL207890A0 (es) |
MX (1) | MX2010010026A (es) |
PL (1) | PL2262838T3 (es) |
RU (1) | RU2540013C2 (es) |
SG (1) | SG10201503135RA (es) |
WO (1) | WO2009124815A1 (es) |
ZA (1) | ZA201007216B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7832566B2 (en) | 2002-05-24 | 2010-11-16 | Biomet Biologics, Llc | Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles |
US20060278588A1 (en) | 2002-05-24 | 2006-12-14 | Woodell-May Jennifer E | Apparatus and method for separating and concentrating fluids containing multiple components |
EP1460088A1 (en) | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
US8034014B2 (en) | 2007-03-06 | 2011-10-11 | Biomet Biologics, Llc | Angiogenesis initation and growth |
US20080269762A1 (en) * | 2007-04-25 | 2008-10-30 | Biomet Manufacturing Corp. | Method and device for repair of cartilage defects |
EP2567692B1 (en) | 2008-02-27 | 2016-04-06 | Biomet Biologics, LLC | Use of a device for obtaining interleukin-1 receptor antagonist rich solutions |
US8753690B2 (en) | 2008-02-27 | 2014-06-17 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
AU2009224690B2 (en) * | 2008-03-13 | 2014-10-09 | Biotest Ag | Agent for treating disease |
BRPI0909048A2 (pt) * | 2008-03-13 | 2015-11-24 | Biotest Ag | composição farmacêutica, e, método de tratamento de uma doença autoimune |
CA2738598C (en) * | 2008-09-29 | 2017-11-21 | Biotest Ag | Composition for treating disease |
US20110052561A1 (en) * | 2009-08-27 | 2011-03-03 | Biomet Biologics,LLC | Osteolysis treatment |
EP2470162B1 (en) | 2009-08-27 | 2019-03-27 | Biomet Biologics, LLC | Implantable device for production of interleukin-1 receptor antagonist |
GB0920944D0 (en) * | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
CA2810202C (en) | 2010-09-03 | 2018-02-20 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
US20140112883A1 (en) * | 2011-04-20 | 2014-04-24 | Liquidating Trust | Methods for reducing an adverse immune response to a foreign antigen in a human subject with anti-cd4 antibodies or cd4-binding fragments thereof or cd4-binding molecules |
US9011846B2 (en) | 2011-05-02 | 2015-04-21 | Biomet Biologics, Llc | Thrombin isolated from blood and blood fractions |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
WO2015081253A1 (en) | 2013-11-26 | 2015-06-04 | Biomet Biologics, Llc | Methods of mediating macrophage phenotypes |
US10441635B2 (en) | 2014-11-10 | 2019-10-15 | Biomet Biologics, Llc | Methods of treating pain using protein solutions |
US9763800B2 (en) | 2015-03-18 | 2017-09-19 | Biomet C. V. | Implant configured for hammertoe and small bone fixation |
CN111373260A (zh) * | 2017-06-22 | 2020-07-03 | 得克萨斯大学体系董事会 | 产生调节性免疫细胞的方法及其用途 |
GB202017681D0 (en) | 2020-11-09 | 2020-12-23 | T Balance Therapeutics Gmbh | Anti-CD4 antibody or fragment thereof for medical use |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT90657B (pt) | 1988-05-27 | 1995-03-01 | Ortho Pharma Corp | Processo para a preparacao de peptidos que bloqueiam a ligacao de hiv-1 a proteina cd4 receptora |
JPH0768273B2 (ja) | 1988-12-02 | 1995-07-26 | カルピス食品工業株式会社 | 抗hivペプチド |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
AU5656890A (en) | 1989-05-02 | 1990-11-29 | Genelabs Incorporated | Chemically modified cd4 peptide fragments having anti-retroviral properties |
US5690933A (en) * | 1989-05-31 | 1997-11-25 | Glaxo Wellcome Inc. | Monoclonal antibodies for inducing tolerance |
GB8912497D0 (en) | 1989-05-31 | 1989-07-19 | Cobbold Stephen P | Monoclonal antibodies |
US20020099179A1 (en) * | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
HUT60768A (en) | 1990-03-16 | 1992-10-28 | Sandoz Ag | Process for producing cd25 fixing molecules |
US7084260B1 (en) * | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
DK0512112T3 (da) * | 1990-11-27 | 1997-09-29 | Biogen Inc | Anti-CD4-antistoffer, som blokerer HIV-inducerede syncytier |
US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
JPH05244982A (ja) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5777085A (en) * | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
IL101769A (en) | 1992-05-03 | 2007-02-11 | Yeda Res & Dev | Modulation of TNF receptor action |
US6270766B1 (en) * | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
JP3616091B2 (ja) | 1992-10-08 | 2005-02-02 | ザ ケネディー インスティチュート オブ リューマトロジー | 自己免疫疾患および炎症性疾患の治療 |
ES2159529T5 (es) * | 1993-03-05 | 2011-03-09 | Bayer Corporation | Anticuerpos monoclonales humanos anti-tnf alfa. |
EP0631783A1 (en) | 1993-06-03 | 1995-01-04 | Mitsubishi Chemical Corporation | Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives |
JPH09510952A (ja) | 1993-10-06 | 1997-11-04 | ザ ケネディー インスティチュート オブ リューマトロジー | 自己免疫疾患および炎症性疾患の治療 |
US20020068057A1 (en) * | 1994-03-10 | 2002-06-06 | Marc Feldmann | Treatment of autoimmune and inflammatory disorders |
EP0840618B1 (en) | 1995-05-18 | 2003-04-23 | Ortho-McNeil Pharmaceutical, Inc. | Induction of immunological tolerance by the use of non-depleting anti-cd4 antibodies |
CN1300173C (zh) | 1996-02-09 | 2007-02-14 | 艾博特生物技术有限公司 | 结合人TNFα的人抗体 |
US20010056066A1 (en) * | 1996-07-26 | 2001-12-27 | Smithkline Beecham Corporation | Method of treating immune cell mediated systemic diseases |
WO1998014211A1 (en) | 1996-10-01 | 1998-04-09 | Celltech Therapeutics Limited | Pharmaceutical products containing protein-tyrosine kinase inhibitors and anti-cd4 antibodies |
US6037454A (en) * | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
DE19722888A1 (de) * | 1997-05-28 | 1998-12-03 | Thomas Prof Dr Huenig | Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten |
WO2000058362A1 (en) | 1999-03-26 | 2000-10-05 | Human Genome Sciences, Inc. | Neutrokine-alpha binding proteins and methods based thereon |
DE60042785D1 (de) * | 1999-06-09 | 2009-10-01 | Immunomedics Inc | Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern |
US7304127B2 (en) | 1999-08-27 | 2007-12-04 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use |
WO2001016182A2 (en) | 1999-08-27 | 2001-03-08 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | POLYPEPTIDES THAT BIND HIV gp120 AND RELATED NUCLEIC ACIDS, ANTIBODIES, COMPOSITIONS, AND METHODS OF USE |
AU2001275186A1 (en) | 2000-06-02 | 2001-12-17 | Nicole Kirchhof | Immunotherapeutic method to prevent islet cell rejection |
CN1592645A (zh) | 2000-09-18 | 2005-03-09 | 拜奥根Idec公司 | 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法 |
DE10050935A1 (de) * | 2000-10-11 | 2002-05-02 | Tegenero Gmbh | Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen |
RU2285541C2 (ru) * | 2000-12-22 | 2006-10-20 | Байоджен Айдек Инк. | Комбинированная терапия для лечения аутоиммунных заболеваний с использованием комбинации элиминирующего в-клетки/иммунорегуляторного антител |
DE60237671D1 (de) | 2001-01-16 | 2010-10-28 | Vascular Therapies Llc | Implantierbare vorrichtung enthaltend resorbierbares matrixmaterial und antiproliferative wirkstoffe zur vorbeugung oder behandlung von versagen vaskulärer hämodialysezugänge und anderer vaskulärer transplantate |
IL157794A0 (en) * | 2001-03-07 | 2004-03-28 | Childrens Medical Center | Method to screen peptide display libraries using minicell display |
EP1241249A1 (en) | 2001-03-12 | 2002-09-18 | Gerold Schuler | CD4+CD25+regulatory T cells from human blood |
JP4660067B2 (ja) | 2001-04-24 | 2011-03-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗血管新生剤とTNFαとを用いる組合せ療法 |
GB2376466A (en) | 2001-06-14 | 2002-12-18 | Mark Frewin | TRX1 antibody |
US7541443B2 (en) * | 2001-06-14 | 2009-06-02 | Tolerrx, Inc. | Anti-CD4 antibodies |
ATE490783T1 (de) | 2001-06-14 | 2010-12-15 | Isis Innovation | Nicht-depletierender antikörper trx-1 gegen cd4 und dessen verwendungen |
DK1451224T3 (da) * | 2001-12-04 | 2012-11-19 | Theramab Llc | Peptid eller protein, der indeholder en C´-D-sløjfe fra CD28-receptorfamilien |
DE10212108A1 (de) * | 2002-03-13 | 2003-10-02 | Tegenero Ag | Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung |
DE10230223A1 (de) * | 2002-07-04 | 2004-01-22 | Tegenero Ag | Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern |
CA2498274A1 (en) | 2002-09-16 | 2004-03-25 | Genentech, Inc. | Compositions and methods for the diagnosis of immune related diseases using pro7 |
US7388079B2 (en) | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
US7501494B2 (en) * | 2003-01-15 | 2009-03-10 | United Biomedical, Inc. | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
EP1460088A1 (en) * | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
RU2358762C9 (ru) * | 2003-04-09 | 2016-10-10 | Джинентех, Инк. | Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа |
GB0314461D0 (en) * | 2003-06-20 | 2003-07-23 | Isis Innovation | Suppression of transplant rejection |
EP1658308A1 (en) | 2003-08-25 | 2006-05-24 | Pieris ProteoLab AG | Muteins of a bilin-binding protein with affinity for a given target |
EP1600164A3 (de) * | 2003-09-22 | 2006-05-17 | TeGenero AG | Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung |
DE10352900A1 (de) * | 2003-11-11 | 2005-06-16 | Tegenero Ag | Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL |
WO2006002377A2 (en) | 2004-06-22 | 2006-01-05 | Tolerrx, Inc. | Optimized dosing with anti-cd4 antibodies for tolerance induction in primates |
JPWO2006035876A1 (ja) * | 2004-09-29 | 2008-05-15 | 興和株式会社 | 関節リウマチの予防及び/又は治療薬 |
WO2006050949A2 (de) | 2004-11-11 | 2006-05-18 | Tegenero Ag | Superagonistische anti-cd28 antikörper |
US8119589B2 (en) | 2004-11-12 | 2012-02-21 | University Of North Carolina At Charlotte | Modulation of CD4+ T cell responses by a tick saliva protein, Salp15 and polypeptides derived therefrom |
DE102004063494A1 (de) * | 2004-12-23 | 2006-07-13 | Tegenero Ag | Antikörper |
JP4730733B2 (ja) * | 2005-05-02 | 2011-07-20 | 国立大学法人京都大学 | 4型葉酸受容体の発現を指標とした制御性t細胞の検出方法、及び免疫賦活剤 |
SG177944A1 (en) * | 2005-07-11 | 2012-02-28 | Macrogenics Inc | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
JP5230420B2 (ja) | 2005-08-18 | 2013-07-10 | ゲンマブ エー/エス | Cd4結合ペプチドおよび放射線による治療 |
US20070071745A1 (en) * | 2005-08-26 | 2007-03-29 | Pablo Umana | Modified antigen binding molecules with altered cell signaling activity |
US8101365B2 (en) | 2006-01-05 | 2012-01-24 | Genentech, Inc. | Anti-EphB4 antibodies and methods using same |
BRPI0708902A2 (pt) | 2006-03-16 | 2011-06-14 | Genentech Inc | mÉtodos de tratar lupus usando anticorpos cd4 |
WO2007111661A2 (en) | 2006-03-20 | 2007-10-04 | Xoma Technology Ltd. | Human antibodies specific for gastrin materials and methods |
WO2007117602A2 (en) | 2006-04-07 | 2007-10-18 | Biogen Idec Ma Inc. | Isolation and use of human regulatory t cells |
WO2007135684A2 (en) | 2006-05-22 | 2007-11-29 | Hadasit Medical Research Services & Development Limited | Method of treatment of anti-cd4 autoimmunity |
US8557533B2 (en) | 2007-02-01 | 2013-10-15 | Helmut Jonuleit | Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4 |
EP2599791A1 (en) | 2007-04-27 | 2013-06-05 | Genentech, Inc. | Potent, stable and non-immunosuppressive anti-CD4 antibodies |
AU2009224690B2 (en) * | 2008-03-13 | 2014-10-09 | Biotest Ag | Agent for treating disease |
BRPI0909048A2 (pt) * | 2008-03-13 | 2015-11-24 | Biotest Ag | composição farmacêutica, e, método de tratamento de uma doença autoimune |
EP2101173A1 (en) | 2008-03-14 | 2009-09-16 | Vivalis | In vitro method to determine whether a drug candidate active against a target protein is active against a variant of said protein |
US8951793B2 (en) | 2008-08-21 | 2015-02-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of making an isolated population of FOXP3+ regulatory T cells |
ES2335381B1 (es) | 2008-09-24 | 2011-02-28 | Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron | Metodo in vitro y kit para el pronostico o prediccion de la respuestapor parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor tnfalfa. |
CA2738598C (en) * | 2008-09-29 | 2017-11-21 | Biotest Ag | Composition for treating disease |
-
2009
- 2009-03-10 AU AU2009235622A patent/AU2009235622C9/en not_active Ceased
- 2009-03-10 EP EP09729626.3A patent/EP2262838B1/en active Active
- 2009-03-10 ES ES09729626.3T patent/ES2569217T3/es active Active
- 2009-03-10 CN CN2009801173062A patent/CN102027016A/zh active Pending
- 2009-03-10 MX MX2010010026A patent/MX2010010026A/es active IP Right Grant
- 2009-03-10 WO PCT/EP2009/052811 patent/WO2009124815A1/en active Application Filing
- 2009-03-10 PL PL09729626.3T patent/PL2262838T3/pl unknown
- 2009-03-10 SG SG10201503135RA patent/SG10201503135RA/en unknown
- 2009-03-10 CA CA2718191A patent/CA2718191C/en active Active
- 2009-03-10 KR KR1020107022911A patent/KR20100135807A/ko not_active Application Discontinuation
- 2009-03-10 JP JP2010550183A patent/JP5795167B2/ja active Active
- 2009-03-10 BR BRPI0909180A patent/BRPI0909180A2/pt not_active Application Discontinuation
- 2009-03-10 HU HUE09729626A patent/HUE028962T2/en unknown
- 2009-03-10 RU RU2010141858/10A patent/RU2540013C2/ru not_active IP Right Cessation
-
2010
- 2010-08-31 IL IL207890A patent/IL207890A0/en unknown
- 2010-09-13 US US12/880,623 patent/US9512226B2/en active Active
- 2010-10-08 ZA ZA2010/07216A patent/ZA201007216B/en unknown
- 2010-10-13 CO CO10127112A patent/CO6311006A2/es not_active Application Discontinuation
-
2011
- 2011-05-25 HK HK11105223.5A patent/HK1151533A1/zh not_active IP Right Cessation
-
2014
- 2014-01-17 JP JP2014006520A patent/JP2014122224A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU2009235622A1 (en) | 2009-10-15 |
HUE028962T2 (en) | 2017-01-30 |
HK1151533A1 (zh) | 2012-02-03 |
RU2010141858A (ru) | 2012-04-20 |
PL2262838T3 (pl) | 2016-10-31 |
AU2009235622C9 (en) | 2015-07-02 |
AU2009235622B2 (en) | 2014-10-23 |
MX2010010026A (es) | 2011-03-21 |
RU2540013C2 (ru) | 2015-01-27 |
JP2011515345A (ja) | 2011-05-19 |
CN102027016A (zh) | 2011-04-20 |
WO2009124815A1 (en) | 2009-10-15 |
CA2718191C (en) | 2018-05-15 |
US20110059082A1 (en) | 2011-03-10 |
JP5795167B2 (ja) | 2015-10-14 |
EP2262838B1 (en) | 2016-04-13 |
ES2569217T3 (es) | 2016-05-09 |
BRPI0909180A2 (pt) | 2016-08-09 |
ZA201007216B (en) | 2016-08-31 |
AU2009235622C1 (en) | 2015-06-04 |
CA2718191A1 (en) | 2009-10-15 |
SG10201503135RA (en) | 2015-06-29 |
KR20100135807A (ko) | 2010-12-27 |
IL207890A0 (en) | 2010-12-30 |
US9512226B2 (en) | 2016-12-06 |
EP2262838A1 (en) | 2010-12-22 |
JP2014122224A (ja) | 2014-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6311006A2 (es) | Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas | |
CO6311007A2 (es) | Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+, efectiva a dosis bajas | |
CO6311008A2 (es) | Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ | |
AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
TN2015000174A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
NZ604029A (en) | Methods of treating bladder cancer | |
AR068185A1 (es) | Composiciones de tabletas de desintegracion oral de lamotrigina | |
PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
CO7101246A2 (es) | Compuesto de carbamato y preparación y uso de los mismos | |
CU23821A3 (es) | Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer | |
MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
CO6670567A2 (es) | Métodos de tratamiento contra el cáncer pancreático | |
MX2011007589A (es) | Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. | |
CO6300964A2 (es) | Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano | |
AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
MX358491B (es) | Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa. | |
AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
AR077125A1 (es) | Combinaciones farmaceuticas utiles para tratar el vhc | |
CO7151496A2 (es) | Agentes terapeúticos para administración subcutánea optimizados | |
NZ715686A (en) | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease | |
AR089509A1 (es) | Metodo para tratar la perdida osea alveolar, un implante dental, un anticuerpo antiesclerostina, un gel o matriz que comprende dicho anticuerpo y uso | |
CO6771406A2 (es) | Una composición combinada | |
BR112014020271A8 (pt) | Composição farmacêutica e métodos para diminuir a frequência de micção em paciente | |
GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
CR20110226A (es) | Composición para tratar enfermedad |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |